Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Brooks Automation assumed with a Buy at Needham » 08:00
05/07/21
05/07
08:00
05/07/21
08:00
BRKS

Brooks Automation

$94.51 /

-0.25 (-0.26%)

Needham analyst David…

Needham analyst David Saxon assumed coverage of Brooks Automation with a Buy rating and $110 price target. The analyst expects the company to deliver margin upside driven primarily by its Life Sciences business as he estimates that Brooks Automation can produce double-digit earnings growth over the next few years.

ShowHide Related Items >><<
BRKS Brooks Automation
$94.51 /

-0.25 (-0.26%)

BRKS Brooks Automation
$94.51 /

-0.25 (-0.26%)

04/05/21 B. Riley
Brooks Automation price target raised to $125 from $105 at B. Riley Securities
02/10/21 KeyBanc
Brooks Automation price target raised to $111 from $99 at KeyBanc
02/03/21 Credit Suisse
Brooks Automation price target raised to $70 from $58 at Credit Suisse
02/03/21 B. Riley
Brooks Automation price target raised to $105 from $100 at B. Riley Securities
BRKS Brooks Automation
$94.51 /

-0.25 (-0.26%)

BRKS Brooks Automation
$94.51 /

-0.25 (-0.26%)

BRKS Brooks Automation
$94.51 /

-0.25 (-0.26%)

Earnings
Sutro Biopharma reports Q1 EPS (66c), consensus (60c) » 07:10
05/07/21
05/07
07:10
05/07/21
07:10
STRO

Sutro Biopharma

$18.50 /

-0.81 (-4.19%)

Reports Q1 revenue…

Reports Q1 revenue $14.7M, consensus $5.73M. As of March 31, Sutro had cash, cash equivalents and marketable securities of $294.9M vs. $326.5M as of December 31, 2020, with projected runway into the second half of 2023. "We are enthusiastic about the meaningful clinical benefit of STRO-002, our FolRalpha-targeting Antibody-Drug Conjugate (ADC), for women with advanced ovarian cancer, as demonstrated by the Phase 1 dose-escalation data, and look forward to providing follow-up data at ASCO," said Bill Newell, Sutro's Chief Executive Officer. "We continue to enroll patients for the dose-expansion portion of the Phase 1 study and we have activated additional clinical sites. STRO-002 is one of the four product candidates in the clinic that were discovered, developed, and are manufactured using our proprietary and integrated cell-free protein synthesis platform. We intend to continue creating value by leveraging our platform to deliver on therapeutics that are precise, rationally designed, and homogenous, for a broad set of patients with unmet medical needs."

ShowHide Related Items >><<
STRO Sutro Biopharma
$18.50 /

-0.81 (-4.19%)

STRO Sutro Biopharma
$18.50 /

-0.81 (-4.19%)

01/28/21 Truist
Sutro Biopharma price target raised to $37 from $24 at Truist
12/02/20 Stifel
Sutro Biopharma initiated with a Buy at Stifel
11/06/20 Piper Sandler
Sutro Biopharma price target raised to $22 from $20 at Piper Sandler
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
  • 09
    Dec
  • 12
    May
STRO Sutro Biopharma
$18.50 /

-0.81 (-4.19%)

STRO Sutro Biopharma
$18.50 /

-0.81 (-4.19%)

Over a week ago
Periodicals
Betaville M&A blog issues 'Uncooked Alert' on Brooks Automation rumor » 13:05
04/30/21
04/30
13:05
04/30/21
13:05
BRKS

Brooks Automation

$103.41 /

+0.44 (+0.43%)

Ben Harrington's…

Ben Harrington's Betaville blog, which focuses on merger and acquisitions news, has issued an "Uncooked Alert" to its subscribers regarding a rumor related to Brooks Automation. Harrington defines an "Uncooked Alert" as: "Market gossip as Betaville receives it. This scuttlebutt has just come in and hasn't been checked with all of Betaville's well-informed RARE sources let alone formal journalistic channels (public relations executives, bankers etc). The rumour might be total codswallop, rubbish or nonsense - but then again there may be something in it, so it's worth airing on Betaville." Reference Link

ShowHide Related Items >><<
BRKS Brooks Automation
$103.41 /

+0.44 (+0.43%)

BRKS Brooks Automation
$103.41 /

+0.44 (+0.43%)

04/05/21 B. Riley
Brooks Automation price target raised to $125 from $105 at B. Riley Securities
02/10/21 KeyBanc
Brooks Automation price target raised to $111 from $99 at KeyBanc
02/03/21 Credit Suisse
Brooks Automation price target raised to $70 from $58 at Credit Suisse
02/03/21 B. Riley
Brooks Automation price target raised to $105 from $100 at B. Riley Securities
BRKS Brooks Automation
$103.41 /

+0.44 (+0.43%)

BRKS Brooks Automation
$103.41 /

+0.44 (+0.43%)

Hot Stocks
Brooks Automation to acquire Precise Automation for $70M in cash » 07:01
04/26/21
04/26
07:01
04/26/21
07:01
BRKS

Brooks Automation

$102.71 /

+3.49 (+3.52%)

Brooks Automation…

Brooks Automation announced that it has entered a definitive agreement to acquire Precise Automation, a developer of collaborative robots and automation subsytems headquartered in Fremont, CA. The total cash purchase price for the acquisiton will be approximately $70M, subject to working capital and other adjustments. The transaction is expected to close by the end of April upon satisfaction of customary closing conditions.

ShowHide Related Items >><<
BRKS Brooks Automation
$102.71 /

+3.49 (+3.52%)

BRKS Brooks Automation
$102.71 /

+3.49 (+3.52%)

04/05/21 B. Riley
Brooks Automation price target raised to $125 from $105 at B. Riley Securities
02/10/21 KeyBanc
Brooks Automation price target raised to $111 from $99 at KeyBanc
02/03/21 Credit Suisse
Brooks Automation price target raised to $70 from $58 at Credit Suisse
02/03/21 B. Riley
Brooks Automation price target raised to $105 from $100 at B. Riley Securities
BRKS Brooks Automation
$102.71 /

+3.49 (+3.52%)

BRKS Brooks Automation
$102.71 /

+3.49 (+3.52%)

Initiation
Stoke Therapeutics assumed with an Outperform at Credit Suisse » 06:46
04/26/21
04/26
06:46
04/26/21
06:46
STOK

Stoke Therapeutics

$31.68 /

+0.575 (+1.85%)

Credit Suisse analyst…

Credit Suisse analyst Judah Frommer assumed coverage of Stoke Therapeutics with an unchanged Outperform rating and $58 price target.

ShowHide Related Items >><<
STOK Stoke Therapeutics
$31.68 /

+0.575 (+1.85%)

STOK Stoke Therapeutics
$31.68 /

+0.575 (+1.85%)

03/29/21 Canaccord
Stoke Therapeutics weakness a buying opportunity, says Canaccord
03/11/21 Canaccord
Stoke Therapeutics price target raised to $76 from $72 at Canaccord
03/10/21 Credit Suisse
Stoke Therapeutics price target raised to $58 from $49 at Credit Suisse
02/10/21 Wedbush
Stoke Therapeutics downgraded to Neutral at Wedbush
STOK Stoke Therapeutics
$31.68 /

+0.575 (+1.85%)

  • 20
    Nov
STOK Stoke Therapeutics
$31.68 /

+0.575 (+1.85%)

Hot Stocks
Nabriva announces start of exclusive distribution of Sivextro in U.S. » 12:15
04/15/21
04/15
12:15
04/15/21
12:15
NBRV

Nabriva Therapeutics

$1.45 /

-0.03 (-2.03%)

, MRK

Merck

$76.97 /

+0.57 (+0.75%)

Nabriva Therapeutics…

Nabriva Therapeutics (NBRV) announced that it has begun exclusive distribution of Sivextro in the United States. Sivextro is now listed in the National Drug Code Directory under the Nabriva label. Since April 12, 2021, Nabriva has been marketing and distributing Sivextro in the United States and certain of its territories as part of an exclusive agreement signed in July 2020 with subsidiaries of Merck (MRK), the company noted. Under the terms of the agreement with Merck, Nabriva will continue to procure Sivextro from Merck and be solely responsible for marketing, sales, and distribution of Sivextro in the United States at least through December 31, 2023, with renewable three-year extensions. As a result, Nabriva expects to recognize 100% of net product sales of Sivextro in its results of operations beginning on April 12, 2021, the company said.

ShowHide Related Items >><<
NBRV Nabriva Therapeutics
$1.45 /

-0.03 (-2.03%)

MRK Merck
$76.97 /

+0.57 (+0.75%)

NBRV Nabriva Therapeutics
$1.45 /

-0.03 (-2.03%)

03/12/21 Northland
Nabriva Therapeutics price target lowered to $6 from $9 at Northland
06/22/20 Northland
Nabriva Therapeutics price target lowered to $1.50 from $2.50 at Northland
04/23/20 Northland
Nabriva Therapeutics price target lowered to $2.50 from $5 at Northland
MRK Merck
$76.97 /

+0.57 (+0.75%)

04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/08/21 Alliance Global Partners
Alliance Global Partners sees Fast Track for Immutep efti as meaningful positive
04/08/21 H.C. Wainwright
Alkermes collaboration not as big as investors wanted, says H.C. Wainwright
04/07/21 Mizuho
Mizuho sees Alkermes, Merck collaboration as important next step for nemvaleukin
NBRV Nabriva Therapeutics
$1.45 /

-0.03 (-2.03%)

MRK Merck
$76.97 /

+0.57 (+0.75%)

  • 11
    Dec
MRK Merck
$76.97 /

+0.57 (+0.75%)

NBRV Nabriva Therapeutics
$1.45 /

-0.03 (-2.03%)

MRK Merck
$76.97 /

+0.57 (+0.75%)

NBRV Nabriva Therapeutics
$1.45 /

-0.03 (-2.03%)

MRK Merck
$76.97 /

+0.57 (+0.75%)

Hot Stocks
Sutro Biopharma earns $15M milestone payment from Merck » 07:04
04/15/21
04/15
07:04
04/15/21
07:04
STRO

Sutro Biopharma

$19.88 /

+0.83 (+4.36%)

, MRK

Merck

$76.40 /

-0.01 (-0.01%)

Sutro Biopharma (STRO)…

Sutro Biopharma (STRO) announced that Merck (MRK) will make to Sutro a $15M milestone payment for the initiation of an IND enabling toxicology study for the first program in its collaboration to develop novel cytokine derivative therapeutics for cancer and autoimmune disorders. In July 2018, Sutro entered into a collaboration with Merck to jointly discover and develop best-in-class immune-modulating cytokine derivatives for both oncology and autoimmune indications.

ShowHide Related Items >><<
STRO Sutro Biopharma
$19.88 /

+0.83 (+4.36%)

MRK Merck
$76.40 /

-0.01 (-0.01%)

STRO Sutro Biopharma
$19.88 /

+0.83 (+4.36%)

01/28/21 Truist
Sutro Biopharma price target raised to $37 from $24 at Truist
12/02/20 Stifel
Sutro Biopharma initiated with a Buy at Stifel
11/06/20 Piper Sandler
Sutro Biopharma price target raised to $22 from $20 at Piper Sandler
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
MRK Merck
$76.40 /

-0.01 (-0.01%)

04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/08/21 Alliance Global Partners
Alliance Global Partners sees Fast Track for Immutep efti as meaningful positive
04/08/21 H.C. Wainwright
Alkermes collaboration not as big as investors wanted, says H.C. Wainwright
04/07/21 Mizuho
Mizuho sees Alkermes, Merck collaboration as important next step for nemvaleukin
STRO Sutro Biopharma
$19.88 /

+0.83 (+4.36%)

MRK Merck
$76.40 /

-0.01 (-0.01%)

  • 09
    Dec
  • 12
    May
MRK Merck
$76.40 /

-0.01 (-0.01%)

STRO Sutro Biopharma
$19.88 /

+0.83 (+4.36%)

MRK Merck
$76.40 /

-0.01 (-0.01%)

STRO Sutro Biopharma
$19.88 /

+0.83 (+4.36%)

MRK Merck
$76.40 /

-0.01 (-0.01%)

Hot Stocks
Bolt Biotherapeutics announces poster presentation for lead agent BDC-1001 » 16:10
04/11/21
04/11
16:10
04/11/21
16:10
BOLT

Bolt Biotherapeutics

$23.17 /

-0.85 (-3.54%)

Bolt Biotherapeutics…

Bolt Biotherapeutics announced that an online oral presentation with live Q&A and a Trial in Progress poster presentation for lead agent BDC-1001 are being presented at the American Association for Cancer Research Annual Meeting 2021 being held virtually from April 10-15th. The oral presentation explores immunosuppression mediated by various cells in the tumor microenvironment, as well as the tumor-supportive nature of antigen presenting cells in the TME in preclinical models. Reawakening these immunosuppressed APCs may result in a productive and durable anti-tumor immune response. Bolt is utilizing its Boltbody platform to create immune-stimulating antibody conjugates, such as BDC-1001, that invoke this mechanism and provided complete tumor regression in preclinical tumor models. BDC-1001 is comprised of a tumor antigen-targeting monoclonal antibody (mAb), a trastuzumab biosimilar and an immune-stimulating agent conjugated to each other with a non-cleavable linker. In a series of preclinical studies with BDC-1001, Bolt demonstrated the mechanism of action for their HER2-targeted ISAC. BDC-1001 surrogate was able to eliminate established, treatment-resistant tumors through the engagement of both innate and adaptive immunity. There were no adverse findings in toxicology studies of BDC-1001. A Trial in Progress poster is also being presented, detailing the design of the study: a four-part study with two dose-escalation parts and two dose-expansion parts. The study is evaluating BDC-1001 administered intravenously with or without an immune checkpoint inhibitor targeting PD-1 in up to 390 patients with HER2-expressing or HER2-amplified advanced or metastatic solid tumors. The dose escalation parts will evaluate sequential doses of BDC-1001 as a monotherapy or in combination with a PD-1 checkpoint inhibitor in a 3+3 design, with the ability to backfill up to an additional 12 patients in each dose cohort. The dose expansion parts will evaluate the recommended Phase 2 dose as monotherapy or in combination with a PD-1 checkpoint inhibitor in four cohorts of patients. The primary objective of the dose escalation portion of the study is to assess safety as measured by the incidence of adverse events and serious adverse events; dose-limiting toxicities within the 3+3 design; and potential immune-related toxicities and determine the recommended phase 2 dose. Secondary objectives will evaluate pharmacokinetic parameters and pharmacodynamic biomarkers in tumor tissue and in peripheral blood associated with drug exposure. These exploratory studies will help reinforce the ISAC mechanism of action in humans and seek to identify biomarkers associated with BDC-1001 biological activity with or without an immune checkpoint inhibitor. In January, Bolt presented a preliminary clinical update on the first 20 patients that showed early signs of clinical activity, including stable disease in several patients and a confirmed partial response by RECIST, and acceptable safety with all 20 patients completing their dose-limiting toxicity evaluation period without DLTs or drug-related serious adverse events. Treatment-emergent adverse events deemed to be related to BDC-1001 have been mild or moderate in severity, including mild infusion-related reactions without interruption to dosing. Bolt expects to provide an update on the trial sometime in the second half of 2021.

ShowHide Related Items >><<
BOLT Bolt Biotherapeutics
$23.17 /

-0.85 (-3.54%)

03/02/21
Fly Intel: Top five analyst initiations
03/02/21 SVB Leerink
Bolt Biotherapeutics initiated with an Outperform at SVB Leerink
03/02/21 Morgan Stanley
Bolt Biotherapeutics initiated with an Overweight at Morgan Stanley
03/02/21 Stifel
Bolt Biotherapeutics initiated with a Buy at Stifel
BOLT Bolt Biotherapeutics
$23.17 /

-0.85 (-3.54%)

  • 05
    Feb
BOLT Bolt Biotherapeutics
$23.17 /

-0.85 (-3.54%)

Conference/Events
Wells Fargo to hold a virtual conference » 04:55
04/08/21
04/08
04:55
04/08/21
04:55
ADAP

Adaptimmune

$4.96 /

-0.3 (-5.70%)

, AGTC

Applied Genetic

$4.45 /

-0.29 (-6.12%)

, BLCM

Bellicum Pharmaceuticals

$3.50 /

-0.12 (-3.31%)

, BEAM

Beam Therapeutics

$74.42 /

-2.26 (-2.95%)

, AVRO

Avrobio

$11.41 /

-0.3 (-2.56%)

, CLLS

Cellectis

$19.28 /

-0.53 (-2.68%)

, CCXI

ChemoCentryx

$48.00 /

-0.79 (-1.62%)

, CALA

Calithera Biosciences

$2.42 /

-0.065 (-2.62%)

, HALO

Halozyme

$42.36 /

-0.175 (-0.41%)

, IMV

IMV Inc.

$2.96 /

-0.235 (-7.36%)

, MORF

Morphic

$60.76 /

-0.6 (-0.98%)

, MRNA

Moderna

$131.52 /

-2 (-1.50%)

, PGEN

Precigen

$6.79 /

-0.24 (-3.41%)

, QURE

uniQure

$34.51 /

-1.41 (-3.93%)

, TCON

Tracon Pharmaceuticals

$8.78 /

-0.18 (-2.01%)

, STRO

Sutro Biopharma

$21.28 /

-1.6 (-6.99%)

, SGMO

Sangamo

$11.24 /

-0.61 (-5.15%)

, RNA

Avidity Biosciences

$23.58 /

-0.97 (-3.95%)

, RGLS

Regulus

$1.44 /

-0.04 (-2.70%)

, ZIOP

Ziopharm

$3.37 /

-0.045 (-1.32%)

Biotech Corporate Access…

Biotech Corporate Access Day Virtual Conference will be held on April 6-8.

ShowHide Related Items >><<
ZIOP Ziopharm
$3.37 /

-0.045 (-1.32%)

TCON Tracon Pharmaceuticals
$8.78 /

-0.18 (-2.01%)

STRO Sutro Biopharma
$21.28 /

-1.6 (-6.99%)

SGMO Sangamo
$11.24 /

-0.61 (-5.15%)

RNA Avidity Biosciences
$23.58 /

-0.97 (-3.95%)

RGLS Regulus
$1.44 /

-0.04 (-2.70%)

QURE uniQure
$34.51 /

-1.41 (-3.93%)

PGEN Precigen
$6.79 /

-0.24 (-3.41%)

MRNA Moderna
$131.52 /

-2 (-1.50%)

MORF Morphic
$60.76 /

-0.6 (-0.98%)

IMV IMV Inc.
$2.96 /

-0.235 (-7.36%)

HALO Halozyme
$42.36 /

-0.175 (-0.41%)

CLLS Cellectis
$19.28 /

-0.53 (-2.68%)

CCXI ChemoCentryx
$48.00 /

-0.79 (-1.62%)

CALA Calithera Biosciences
$2.42 /

-0.065 (-2.62%)

BLCM Bellicum Pharmaceuticals
$3.50 /

-0.12 (-3.31%)

BEAM Beam Therapeutics
$74.42 /

-2.26 (-2.95%)

AVRO Avrobio
$11.41 /

-0.3 (-2.56%)

AGTC Applied Genetic
$4.45 /

-0.29 (-6.12%)

ADAP Adaptimmune
$4.96 /

-0.3 (-5.70%)

ADAP Adaptimmune
$4.96 /

-0.3 (-5.70%)

08/12/20 Piper Sandler
TCR2 Therapeutics initiated with an Overweight at Piper Sandler
06/01/20 Mizuho
Adaptimmune price target raised to $9 from $3 at Mizuho
05/29/20 JonesTrading
JonesTrading upgrades Adaptimmune to Buy after data alleviates 'key concern'
05/29/20 JonesTrading
Adaptimmune upgraded to Buy from Hold at JonesTrading
AGTC Applied Genetic
$4.45 /

-0.29 (-6.12%)

03/01/21 Stifel
Applied Genetic initiated with a Buy at Stifel
02/02/21 H.C. Wainwright
Applied Genetic price target raised to $24 from $18 at H.C. Wainwright
02/01/21 Roth Capital
Applied Genetic price target raised to $35 from $30 at Roth Capital
11/17/20 Roth Capital
Applied Genetic price target raised to $30 from $26 at Roth Capital
BLCM Bellicum Pharmaceuticals
$3.50 /

-0.12 (-3.31%)

10/30/20
Fly Intel: Top five analyst downgrades
10/30/20 Ladenburg
Bellicum Pharmaceuticals downgraded to Neutral from Buy at Ladenburg
10/30/20 Wells Fargo
Bellicum Pharmaceuticals downgraded to Equal Weight from Overweight at Wells Fargo
10/30/20 Wells Fargo
Bellicum downgraded to Equal Weight from Overweight at Wells Fargo
BEAM Beam Therapeutics
$74.42 /

-2.26 (-2.95%)

03/01/21 Barclays
Beam Therapeutics downgraded to Equal Weight from Overweight at Barclays
02/25/21 Wedbush
Beam Therapeutics price target raised to $112 from $42 at Wedbush
02/16/21
Fly Intel: Top five analyst initiations
02/16/21 Wells Fargo
Beam Therapeutics initiated with an Overweight at Wells Fargo
AVRO Avrobio
$11.41 /

-0.3 (-2.56%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/09/21 Barclays
Avrobio initiated with an Overweight at Barclays
03/01/21 Stifel
Avrobio initiated with a Hold at Stifel
02/17/21 Mizuho
Avrobio selloff on Bluebird news a buying opportunity, says Mizuho
CLLS Cellectis
$19.28 /

-0.53 (-2.68%)

03/16/21 Baird
Cellectis upgraded to Outperform from Neutral at Baird
10/15/20 Baird
Cellectis downgraded to Neutral at Baird
10/15/20 Baird
Cellectis downgraded to Neutral from Outperform at Baird
08/19/20
Fly Intel: Top five analyst upgrades
CCXI ChemoCentryx
$48.00 /

-0.79 (-1.62%)

03/26/21 Piper Sandler
ChemoCentryx given FDA panel meeting on May 6, says Piper Sandler
03/02/21 H.C. Wainwright
ChemoCentryx price target raised to $101 from $83 at H.C. Wainwright
03/01/21 Stifel
ChemoCentryx initiated with a Buy at Stifel
12/22/20 Piper Sandler
Piper names ChemoCentryx a top pick for 2021, boosts target to $80
CALA Calithera Biosciences
$2.42 /

-0.065 (-2.62%)

01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform at SVB Leerink
01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform from Outperform at SVB Leerink
01/05/21 Citi
Calithera Biosciences price target lowered to $5 from $10 at Citi
01/05/21 H.C. Wainwright
Calithera Biosciences price target lowered to $4 from $9.50 at H.C. Wainwright
HALO Halozyme
$42.36 /

-0.175 (-0.41%)

01/25/21 BMO Capital
Halozyme price target raised to $65 from $56 at BMO Capital
01/21/21 Benchmark
Halozyme price target raised to $59 from $46 at Benchmark
01/14/21 Piper Sandler
Halozyme price target raised to $50 from $42 at Piper Sandler
01/11/21 Benchmark
Phesgo EU approval/Horizon deal fuel Halozyme increased guidance, says Benchmark
IMV IMV Inc.
$2.96 /

-0.235 (-7.36%)

12/29/20 Raymond James
Raymond James says IMV COVID plans look like 'red herring' to justify delay
07/21/20 Industrial Alliance
IMV Inc. initiated with a Buy at Industrial Alliance
07/14/20 Wells Fargo
IMV Inc. price target raised to $11 from $8.50 at Wells Fargo
05/18/20 Wells Fargo
IMV Inc. upgraded to Overweight on COVID-19 vaccine potential at Wells Fargo
MORF Morphic
$60.76 /

-0.6 (-0.98%)

03/03/21 SVB Leerink
Protagonist Therapeutics price target raised to $41 from $30 at SVB Leerink
03/01/21 Wells Fargo
Morphic Holding price target raised to $103 from $40 at Wells Fargo
02/02/21 RBC Capital
Morphic Holding price target raised to $50 from $35 at RBC Capital
10/26/20 RBC Capital
Morphic Holding initiated with an Outperform at RBC Capital
MRNA Moderna
$131.52 /

-2 (-1.50%)

04/07/21 Jefferies
Catalent pact with Moderna removes potential overhang, says Jefferies
03/15/21 Piper Sandler
Piper Sandler bullish on Moderna as first subject vaccinated in '1283 study
03/01/21 Chardan
Moderna price target raised to $182 from $107 at Chardan
02/26/21 Barclays
Moderna price target raised to $178 from $169 at Barclays
PGEN Precigen
$6.79 /

-0.24 (-3.41%)

03/02/21 B. Riley
Precigen price target raised to $14 from $10 at B. Riley Securities
02/25/21 Stifel
Precigen initiated with a Buy at Stifel
02/22/21 Wells Fargo
Precigen initiated with an Overweight at Wells Fargo
02/18/21
Fly Intel: Top five analyst initiations
QURE uniQure
$34.51 /

-1.41 (-3.93%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Mizuho
uniQure upgraded to Buy on favorable risk/reward at Mizuho
04/01/21 Mizuho
uniQure upgraded to Buy from Neutral at Mizuho
03/29/21 H.C. Wainwright
uniQure probe 'important first step' toward lifting hold, says H.C. Wainwright
TCON Tracon Pharmaceuticals
$8.78 /

-0.18 (-2.01%)

04/01/21 JonesTrading
Tracon Pharmaceuticals initiated with a Buy at JonesTrading
02/10/21
Fly Intel: Top five analyst initiations
02/10/21 Maxim
Tracon Pharmaceuticals initiated with a Buy at Maxim
12/04/20 H.C. Wainwright
Tracon Pharmaceuticals price target raised to $12 from $7 at H.C. Wainwright
STRO Sutro Biopharma
$21.28 /

-1.6 (-6.99%)

01/28/21 Truist
Sutro Biopharma price target raised to $37 from $24 at Truist
12/02/20 Stifel
Sutro Biopharma initiated with a Buy at Stifel
11/06/20 Piper Sandler
Sutro Biopharma price target raised to $22 from $20 at Piper Sandler
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
SGMO Sangamo
$11.24 /

-0.61 (-5.15%)

03/03/21 Wells Fargo
Sangamo price target lowered to $29 from $36 at Wells Fargo
01/05/21 Stifel
Sangamo initiated with a Hold at Stifel
12/16/20 H.C. Wainwright
Sangamo assumed with a Buy at H.C. Wainwright
09/08/20 BofA
Sangamo resumed with a Buy at BofA
RNA Avidity Biosciences
$23.58 /

-0.97 (-3.95%)

07/07/20 Cowen
Avidity Biosciences initiated with an Outperform at Cowen
07/07/20 SVB Leerink
Avidity Biosciences initiated with an Outperform at SVB Leerink
07/07/20 Cowen
Avidity Biosciences initiated with an Outperform at Cowen
07/07/20 Wells Fargo
Avidity Biosciences initiated with an Overweight at Wells Fargo
RGLS Regulus
$1.44 /

-0.04 (-2.70%)

05/04/20 H.C. Wainwright
Regulus price target lowered to $1.50 from $2 at H.C. Wainwright
ZIOP Ziopharm
$3.37 /

-0.045 (-1.32%)

03/12/21 Jefferies
Ziopharm downgraded to Hold from Buy at Jefferies
03/01/21
Fly Intel: Top five analyst downgrades
03/01/21 H.C. Wainwright
Ziopharm downgraded to Neutral from Buy at H.C. Wainwright
07/10/20 Lake Street
Ziopharm took 'important step' with start of CAR-T study, says Lake Street
ZIOP Ziopharm
$3.37 /

-0.045 (-1.32%)

TCON Tracon Pharmaceuticals
$8.78 /

-0.18 (-2.01%)

STRO Sutro Biopharma
$21.28 /

-1.6 (-6.99%)

SGMO Sangamo
$11.24 /

-0.61 (-5.15%)

RNA Avidity Biosciences
$23.58 /

-0.97 (-3.95%)

RGLS Regulus
$1.44 /

-0.04 (-2.70%)

QURE uniQure
$34.51 /

-1.41 (-3.93%)

PGEN Precigen
$6.79 /

-0.24 (-3.41%)

MRNA Moderna
$131.52 /

-2 (-1.50%)

MORF Morphic
$60.76 /

-0.6 (-0.98%)

HALO Halozyme
$42.36 /

-0.175 (-0.41%)

CLLS Cellectis
$19.28 /

-0.53 (-2.68%)

CCXI ChemoCentryx
$48.00 /

-0.79 (-1.62%)

CALA Calithera Biosciences
$2.42 /

-0.065 (-2.62%)

BLCM Bellicum Pharmaceuticals
$3.50 /

-0.12 (-3.31%)

BEAM Beam Therapeutics
$74.42 /

-2.26 (-2.95%)

AVRO Avrobio
$11.41 /

-0.3 (-2.56%)

AGTC Applied Genetic
$4.45 /

-0.29 (-6.12%)

ADAP Adaptimmune
$4.96 /

-0.3 (-5.70%)

  • 03
    Mar
  • 28
    Jan
  • 22
    Jan
  • 16
    Dec
  • 09
    Dec
  • 20
    Nov
  • 01
    Oct
  • 11
    Jun
  • 12
    Jun
  • 02
    Jun
  • 19
    May
  • 12
    May
  • 16
    Apr
MRNA Moderna
$131.52 /

-2 (-1.50%)

ZIOP Ziopharm
$3.37 /

-0.045 (-1.32%)

STRO Sutro Biopharma
$21.28 /

-1.6 (-6.99%)

QURE uniQure
$34.51 /

-1.41 (-3.93%)

PGEN Precigen
$6.79 /

-0.24 (-3.41%)

MRNA Moderna
$131.52 /

-2 (-1.50%)

MORF Morphic
$60.76 /

-0.6 (-0.98%)

HALO Halozyme
$42.36 /

-0.175 (-0.41%)

CCXI ChemoCentryx
$48.00 /

-0.79 (-1.62%)

CALA Calithera Biosciences
$2.42 /

-0.065 (-2.62%)

BLCM Bellicum Pharmaceuticals
$3.50 /

-0.12 (-3.31%)

AVRO Avrobio
$11.41 /

-0.3 (-2.56%)

AGTC Applied Genetic
$4.45 /

-0.29 (-6.12%)

TCON Tracon Pharmaceuticals
$8.78 /

-0.18 (-2.01%)

STRO Sutro Biopharma
$21.28 /

-1.6 (-6.99%)

SGMO Sangamo
$11.24 /

-0.61 (-5.15%)

PGEN Precigen
$6.79 /

-0.24 (-3.41%)

MRNA Moderna
$131.52 /

-2 (-1.50%)

BEAM Beam Therapeutics
$74.42 /

-2.26 (-2.95%)

Conference/Events
Wells Fargo to hold a virtual conference » 04:55
04/07/21
04/07
04:55
04/07/21
04:55
ADAP

Adaptimmune

$5.26 /

-0.35 (-6.24%)

, AGTC

Applied Genetic

$4.74 /

-0.26 (-5.20%)

, BLCM

Bellicum Pharmaceuticals

$3.63 /

-0.08 (-2.16%)

, BEAM

Beam Therapeutics

$76.80 /

-3.74 (-4.64%)

, AVRO

Avrobio

$11.71 /

-0.89 (-7.06%)

, CLLS

Cellectis

$19.80 /

-1.01 (-4.85%)

, CCXI

ChemoCentryx

$48.79 /

-0.65 (-1.31%)

, CALA

Calithera Biosciences

$2.48 /

-0.02 (-0.80%)

, HALO

Halozyme

$42.53 /

-0.33 (-0.77%)

, IMV

IMV Inc.

$3.19 /

-0.03 (-0.93%)

, MORF

Morphic

$60.97 /

-0.38 (-0.62%)

, MRNA

Moderna

$133.51 /

+3.74 (+2.88%)

, PGEN

Precigen

$7.03 /

-0.63 (-8.22%)

, QURE

uniQure

$35.92 /

+0.19 (+0.53%)

, TCON

Tracon Pharmaceuticals

$8.96 /

+0.3 (+3.46%)

, STRO

Sutro Biopharma

$22.88 /

-0.87 (-3.66%)

, SGMO

Sangamo

$11.85 /

-0.79 (-6.25%)

, RNA

Avidity Biosciences

$24.54 /

-0.44 (-1.76%)

, RGLS

Regulus

$1.48 /

-0.03 (-1.99%)

, ZIOP

Ziopharm

$3.42 /

-0.27 (-7.33%)

Biotech Corporate Access…

Biotech Corporate Access Day Virtual Conference will be held on April 6-8.

ShowHide Related Items >><<
ZIOP Ziopharm
$3.42 /

-0.27 (-7.33%)

TCON Tracon Pharmaceuticals
$8.96 /

+0.3 (+3.46%)

STRO Sutro Biopharma
$22.88 /

-0.87 (-3.66%)

SGMO Sangamo
$11.85 /

-0.79 (-6.25%)

RNA Avidity Biosciences
$24.54 /

-0.44 (-1.76%)

RGLS Regulus
$1.48 /

-0.03 (-1.99%)

QURE uniQure
$35.92 /

+0.19 (+0.53%)

PGEN Precigen
$7.03 /

-0.63 (-8.22%)

MRNA Moderna
$133.51 /

+3.74 (+2.88%)

MORF Morphic
$60.97 /

-0.38 (-0.62%)

IMV IMV Inc.
$3.19 /

-0.03 (-0.93%)

HALO Halozyme
$42.53 /

-0.33 (-0.77%)

CLLS Cellectis
$19.80 /

-1.01 (-4.85%)

CCXI ChemoCentryx
$48.79 /

-0.65 (-1.31%)

CALA Calithera Biosciences
$2.48 /

-0.02 (-0.80%)

BLCM Bellicum Pharmaceuticals
$3.63 /

-0.08 (-2.16%)

BEAM Beam Therapeutics
$76.80 /

-3.74 (-4.64%)

AVRO Avrobio
$11.71 /

-0.89 (-7.06%)

AGTC Applied Genetic
$4.74 /

-0.26 (-5.20%)

ADAP Adaptimmune
$5.26 /

-0.35 (-6.24%)

ADAP Adaptimmune
$5.26 /

-0.35 (-6.24%)

08/12/20 Piper Sandler
TCR2 Therapeutics initiated with an Overweight at Piper Sandler
06/01/20 Mizuho
Adaptimmune price target raised to $9 from $3 at Mizuho
05/29/20 JonesTrading
JonesTrading upgrades Adaptimmune to Buy after data alleviates 'key concern'
05/29/20 JonesTrading
Adaptimmune upgraded to Buy from Hold at JonesTrading
AGTC Applied Genetic
$4.74 /

-0.26 (-5.20%)

03/01/21 Stifel
Applied Genetic initiated with a Buy at Stifel
02/02/21 H.C. Wainwright
Applied Genetic price target raised to $24 from $18 at H.C. Wainwright
02/01/21 Roth Capital
Applied Genetic price target raised to $35 from $30 at Roth Capital
11/17/20 Roth Capital
Applied Genetic price target raised to $30 from $26 at Roth Capital
BLCM Bellicum Pharmaceuticals
$3.63 /

-0.08 (-2.16%)

10/30/20
Fly Intel: Top five analyst downgrades
10/30/20 Ladenburg
Bellicum Pharmaceuticals downgraded to Neutral from Buy at Ladenburg
10/30/20 Wells Fargo
Bellicum Pharmaceuticals downgraded to Equal Weight from Overweight at Wells Fargo
10/30/20 Wells Fargo
Bellicum downgraded to Equal Weight from Overweight at Wells Fargo
BEAM Beam Therapeutics
$76.80 /

-3.74 (-4.64%)

03/01/21 Barclays
Beam Therapeutics downgraded to Equal Weight from Overweight at Barclays
02/25/21 Wedbush
Beam Therapeutics price target raised to $112 from $42 at Wedbush
02/16/21
Fly Intel: Top five analyst initiations
02/16/21 Wells Fargo
Beam Therapeutics initiated with an Overweight at Wells Fargo
AVRO Avrobio
$11.71 /

-0.89 (-7.06%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/09/21 Barclays
Avrobio initiated with an Overweight at Barclays
03/01/21 Stifel
Avrobio initiated with a Hold at Stifel
02/17/21 Mizuho
Avrobio selloff on Bluebird news a buying opportunity, says Mizuho
CLLS Cellectis
$19.80 /

-1.01 (-4.85%)

03/16/21 Baird
Cellectis upgraded to Outperform from Neutral at Baird
10/15/20 Baird
Cellectis downgraded to Neutral at Baird
10/15/20 Baird
Cellectis downgraded to Neutral from Outperform at Baird
08/19/20
Fly Intel: Top five analyst upgrades
CCXI ChemoCentryx
$48.79 /

-0.65 (-1.31%)

03/26/21 Piper Sandler
ChemoCentryx given FDA panel meeting on May 6, says Piper Sandler
03/02/21 H.C. Wainwright
ChemoCentryx price target raised to $101 from $83 at H.C. Wainwright
03/01/21 Stifel
ChemoCentryx initiated with a Buy at Stifel
12/22/20 Piper Sandler
Piper names ChemoCentryx a top pick for 2021, boosts target to $80
CALA Calithera Biosciences
$2.48 /

-0.02 (-0.80%)

01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform at SVB Leerink
01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform from Outperform at SVB Leerink
01/05/21 Citi
Calithera Biosciences price target lowered to $5 from $10 at Citi
01/05/21 H.C. Wainwright
Calithera Biosciences price target lowered to $4 from $9.50 at H.C. Wainwright
HALO Halozyme
$42.53 /

-0.33 (-0.77%)

01/25/21 BMO Capital
Halozyme price target raised to $65 from $56 at BMO Capital
01/21/21 Benchmark
Halozyme price target raised to $59 from $46 at Benchmark
01/14/21 Piper Sandler
Halozyme price target raised to $50 from $42 at Piper Sandler
01/11/21 Benchmark
Phesgo EU approval/Horizon deal fuel Halozyme increased guidance, says Benchmark
IMV IMV Inc.
$3.19 /

-0.03 (-0.93%)

12/29/20 Raymond James
Raymond James says IMV COVID plans look like 'red herring' to justify delay
07/21/20 Industrial Alliance
IMV Inc. initiated with a Buy at Industrial Alliance
07/14/20 Wells Fargo
IMV Inc. price target raised to $11 from $8.50 at Wells Fargo
05/18/20 Wells Fargo
IMV Inc. upgraded to Overweight on COVID-19 vaccine potential at Wells Fargo
MORF Morphic
$60.97 /

-0.38 (-0.62%)

03/03/21 SVB Leerink
Protagonist Therapeutics price target raised to $41 from $30 at SVB Leerink
03/01/21 Wells Fargo
Morphic Holding price target raised to $103 from $40 at Wells Fargo
02/02/21 RBC Capital
Morphic Holding price target raised to $50 from $35 at RBC Capital
10/26/20 RBC Capital
Morphic Holding initiated with an Outperform at RBC Capital
MRNA Moderna
$133.51 /

+3.74 (+2.88%)

03/15/21 Piper Sandler
Piper Sandler bullish on Moderna as first subject vaccinated in '1283 study
03/01/21 Chardan
Moderna price target raised to $182 from $107 at Chardan
02/26/21 Barclays
Moderna price target raised to $178 from $169 at Barclays
02/26/21 Brookline
Moderna price target raised to $205 from $180 at Brookline
PGEN Precigen
$7.03 /

-0.63 (-8.22%)

03/02/21 B. Riley
Precigen price target raised to $14 from $10 at B. Riley Securities
02/25/21 Stifel
Precigen initiated with a Buy at Stifel
02/22/21 Wells Fargo
Precigen initiated with an Overweight at Wells Fargo
02/18/21
Fly Intel: Top five analyst initiations
QURE uniQure
$35.92 /

+0.19 (+0.53%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Mizuho
uniQure upgraded to Buy on favorable risk/reward at Mizuho
04/01/21 Mizuho
uniQure upgraded to Buy from Neutral at Mizuho
03/29/21 H.C. Wainwright
uniQure probe 'important first step' toward lifting hold, says H.C. Wainwright
TCON Tracon Pharmaceuticals
$8.96 /

+0.3 (+3.46%)

04/01/21 JonesTrading
Tracon Pharmaceuticals initiated with a Buy at JonesTrading
02/10/21
Fly Intel: Top five analyst initiations
02/10/21 Maxim
Tracon Pharmaceuticals initiated with a Buy at Maxim
12/04/20 H.C. Wainwright
Tracon Pharmaceuticals price target raised to $12 from $7 at H.C. Wainwright
STRO Sutro Biopharma
$22.88 /

-0.87 (-3.66%)

01/28/21 Truist
Sutro Biopharma price target raised to $37 from $24 at Truist
12/02/20 Stifel
Sutro Biopharma initiated with a Buy at Stifel
11/06/20 Piper Sandler
Sutro Biopharma price target raised to $22 from $20 at Piper Sandler
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
SGMO Sangamo
$11.85 /

-0.79 (-6.25%)

03/03/21 Wells Fargo
Sangamo price target lowered to $29 from $36 at Wells Fargo
01/05/21 Stifel
Sangamo initiated with a Hold at Stifel
12/16/20 H.C. Wainwright
Sangamo assumed with a Buy at H.C. Wainwright
09/08/20 BofA
Sangamo resumed with a Buy at BofA
RNA Avidity Biosciences
$24.54 /

-0.44 (-1.76%)

07/07/20 Cowen
Avidity Biosciences initiated with an Outperform at Cowen
07/07/20 SVB Leerink
Avidity Biosciences initiated with an Outperform at SVB Leerink
07/07/20 Cowen
Avidity Biosciences initiated with an Outperform at Cowen
07/07/20 Wells Fargo
Avidity Biosciences initiated with an Overweight at Wells Fargo
RGLS Regulus
$1.48 /

-0.03 (-1.99%)

05/04/20 H.C. Wainwright
Regulus price target lowered to $1.50 from $2 at H.C. Wainwright
ZIOP Ziopharm
$3.42 /

-0.27 (-7.33%)

03/12/21 Jefferies
Ziopharm downgraded to Hold from Buy at Jefferies
03/01/21
Fly Intel: Top five analyst downgrades
03/01/21 H.C. Wainwright
Ziopharm downgraded to Neutral from Buy at H.C. Wainwright
07/10/20 Lake Street
Ziopharm took 'important step' with start of CAR-T study, says Lake Street
ZIOP Ziopharm
$3.42 /

-0.27 (-7.33%)

TCON Tracon Pharmaceuticals
$8.96 /

+0.3 (+3.46%)

STRO Sutro Biopharma
$22.88 /

-0.87 (-3.66%)

SGMO Sangamo
$11.85 /

-0.79 (-6.25%)

RNA Avidity Biosciences
$24.54 /

-0.44 (-1.76%)

RGLS Regulus
$1.48 /

-0.03 (-1.99%)

QURE uniQure
$35.92 /

+0.19 (+0.53%)

PGEN Precigen
$7.03 /

-0.63 (-8.22%)

MRNA Moderna
$133.51 /

+3.74 (+2.88%)

MORF Morphic
$60.97 /

-0.38 (-0.62%)

HALO Halozyme
$42.53 /

-0.33 (-0.77%)

CLLS Cellectis
$19.80 /

-1.01 (-4.85%)

CCXI ChemoCentryx
$48.79 /

-0.65 (-1.31%)

CALA Calithera Biosciences
$2.48 /

-0.02 (-0.80%)

BLCM Bellicum Pharmaceuticals
$3.63 /

-0.08 (-2.16%)

BEAM Beam Therapeutics
$76.80 /

-3.74 (-4.64%)

AVRO Avrobio
$11.71 /

-0.89 (-7.06%)

AGTC Applied Genetic
$4.74 /

-0.26 (-5.20%)

ADAP Adaptimmune
$5.26 /

-0.35 (-6.24%)

  • 03
    Mar
  • 28
    Jan
  • 22
    Jan
  • 16
    Dec
  • 09
    Dec
  • 20
    Nov
  • 01
    Oct
  • 11
    Jun
  • 12
    Jun
  • 02
    Jun
  • 19
    May
  • 12
    May
  • 16
    Apr
MRNA Moderna
$133.51 /

+3.74 (+2.88%)

ZIOP Ziopharm
$3.42 /

-0.27 (-7.33%)

STRO Sutro Biopharma
$22.88 /

-0.87 (-3.66%)

QURE uniQure
$35.92 /

+0.19 (+0.53%)

PGEN Precigen
$7.03 /

-0.63 (-8.22%)

MRNA Moderna
$133.51 /

+3.74 (+2.88%)

MORF Morphic
$60.97 /

-0.38 (-0.62%)

HALO Halozyme
$42.53 /

-0.33 (-0.77%)

CCXI ChemoCentryx
$48.79 /

-0.65 (-1.31%)

CALA Calithera Biosciences
$2.48 /

-0.02 (-0.80%)

BLCM Bellicum Pharmaceuticals
$3.63 /

-0.08 (-2.16%)

AVRO Avrobio
$11.71 /

-0.89 (-7.06%)

AGTC Applied Genetic
$4.74 /

-0.26 (-5.20%)

TCON Tracon Pharmaceuticals
$8.96 /

+0.3 (+3.46%)

STRO Sutro Biopharma
$22.88 /

-0.87 (-3.66%)

SGMO Sangamo
$11.85 /

-0.79 (-6.25%)

PGEN Precigen
$7.03 /

-0.63 (-8.22%)

MRNA Moderna
$133.51 /

+3.74 (+2.88%)

BEAM Beam Therapeutics
$76.80 /

-3.74 (-4.64%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.